Edition:
United States

Dr.Reddy's Laboratories Ltd (RDY.N)

RDY.N on New York Stock Exchange

35.87USD
22 Nov 2017
Change (% chg)

$-0.93 (-2.53%)
Prev Close
$36.80
Open
$36.09
Day's High
$36.10
Day's Low
$35.65
Volume
104,802
Avg. Vol
85,833
52-wk High
$47.75
52-wk Low
$29.85

Chart for

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.41
Market Cap(Mil.): $5,887.12
Shares Outstanding(Mil.): 165.89
Dividend: 0.31
Yield (%): 0.89

Financials

  Industry Sector
P/E (TTM): -- 31.51 15.54
EPS (TTM): -- -- --
ROI: -- 15.16 11.80
ROE: -- 16.57 15.75

BRIEF-Dr.Reddy's Laboratories gets EIR from US FDA for Duvvada facility

* Says got EIR from US FDA for formulations manufacturing facility at Duvvada, Vishakhapatnam‍​

Nov 20 2017

BRIEF-Dr.Reddy's Labs ‍launches clofarabine injection in U.S.

* Says ‍launch of clofarabine injection in U.S. market​ Source text: http://bit.ly/2zBoR7i Further company coverage:

Nov 14 2017

BRIEF-DR. REDDY'S LABORATORIES LAUNCHES GENERIC AZACITIDINE FOR INJECTION IN CANADIAN MARKET

* DR REDDY'S LABORATORIES ANNOUNCES THE LAUNCH OF GENERIC AZACITIDINE FOR INJECTION IN THE CANADIAN MARKET

Nov 02 2017

BRIEF-India's Dr.Reddy's Laboratories Sept-qtr consol PAT down about 1 pct

* Sept quarter consol net profit after tax 3.05 billion rupees versus 3.09 billion rupees last year

Oct 31 2017

BRIEF-Enorama Pharma ‍starts cooperation with Dr. Reddy's Laboratories

* ‍STARTS COOPERATION WITH DR. REDDY'S LABORATORIES ON SALES IN NORTH AMERICA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 12 2017

Indian shares head for 3rd session of gains; automakers jump on Sept sales

Oct 3 Indian shares rose over 1 percent on Tuesday and were headed for a third consecutive session of gains, as automakers such as Tata Motors Ltd surged after posting strong monthly sales, while Dr. Reddy's Laboratories jumped on the launch of a drug in its key U.S. market.

Oct 03 2017

BRIEF-Dr.Reddy's Labs gets EIR from U.S. FDA for plant in Andhra Pradesh

* Says gets EIR from U.S. FDA for formulation Srikakulam plant (SEZ) unit 1, Andhra Pradesh Source text - http://bit.ly/2wleXS9 Further company coverage:

Sep 28 2017

BRIEF-Dr.Reddy's Labs says FDA completes ‍audit of co's Telangana facilities with no observations​

* FDA completes ‍audit of co's Telangana custom pharmaceutical services facility, technology development centre with no observations​ Source text: http://bit.ly/2hhsmbf Further company coverage:

Sep 21 2017

BRIEF-Dr.Reddy's Laboratories gets EIR from US FDA for Formulation Srikakulam plant

* Says received an establishment inspection report (EIR) from US FDA for formulation Srikakulam plant Source text for Eikon: Further company coverage:

Sep 21 2017

Indivior files lawsuits against Suboxone generic rivals

Indivior's U.S. subsidiary has filed lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of the drugmaker's revenue.

Sep 15 2017

Earnings vs. Estimates